Enzastaurin hydrochloride.: Protein kinase C β inhibitor, antiangiogenic agent

被引：9

作者：

Sorbera, L. A. ^{[1
]}

Serradell, N. ^{[1
]}

Bolos, J. ^{[1
]}

Rosa, E. ^{[1
]}

机构：

[1] Prous Sci, Barcelona 08080, Spain

来源：

DRUGS OF THE FUTURE | 2007年 / 32卷 / 04期

关键词：

D O I：

10.1358/dof.2007.032.04.1095514

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Protein kinase C (PKC) overexpression has been linked to several types of cancer, with the PKC beta isoform suspected to be involved in vascular endothelial growth factor (VEGF)-induced tumor development and angiogenesis and in the apoptosis-regulating phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Targeting of PKC beta therefore represents a potentially effective strategy for the treatment of cancer. Enzastaurin (LY-317615) is an acyclic bisindolylmaleimide that potently and selectively inhibits the PKC beta isoform. Enzastaurin displayed anticancer efficacy in several preclinical cancer models and in clinical trials in patients with advanced cancers. It is currently undergoing phase III development for relapsed glioblastoma multiforme and diffuse B-cell lymphoma.

引用

页码：297 / 309

页数：13

共 50 条

[41] Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Robertson, Michael J.
Kahl, Brad S.
Vose, Julie M.
de Vos, Sven
Laughlin, Mary
Flynn, Patrick J.
Rowland, Kendrith
Cruz, Jose C.
Goldberg, Stuart L.
Musib, Luna
Darstein, Christelle
Enas, Nathan
Kutok, Jeffery L.
Aster, Jon C.
Neuberg, Donna
Savage, Kerry J.
LaCasce, Ann
Thornton, Donald
Slapak, Christopher A.
Shipp, Margaret A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1741 - 1746
[42] Niraparib hydrochloride. Poly [ADP-ribose] polymerase (PARP) inhibitor, Oncolytic.
Gras, Jordi
DRUGS OF THE FUTURE, 2013, 38 (10) : 679 - 685
[43] IVERMECTIN - AN INHIBITOR OF PROTEIN-KINASE-C
ELLIS, C
NATHWANI, B
MORRICE, N
PARKER, P
EVANS, FJ
AITKEN, A
TROPICAL MEDICINE AND PARASITOLOGY, 1986, 37 (01): : 77 - 77
[44] Enzastaurin, an oral protein kinase CP inhibitor with potential activity in diffuse large B-cell lymphoma
Reddy, GK
CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (04): : 265 - 267
[45] The protein kinase C beta (PKCβ) inhibitor enzastaurin HCl (LY317615) augments chemosensitivity of multiple myeloma (MM) cells to dexamethasone and the proteasome inhibitor bortezomib.
Suvannasankha, A
Xu, DW
Abonour, R
BLOOD, 2004, 104 (11) : 179B - 179B
[46] Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Van der Steen, Nele
Potze, Lisette
Giovannetti, Elisa
Cavazzoni, Andrea
Ruijtenbeek, Rob
Rolfo, Christian
Pauwels, Patrick
Peters, Godefridus J.
AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (04): : 816 - 830
[47] A concise synthesis of a novel antiangiogenic tyrosine kinase inhibitor
Payack, JF
Vazquez, E
Matty, L
Kress, MH
McNamara, J
JOURNAL OF ORGANIC CHEMISTRY, 2005, 70 (01): : 175 - 178
[48] A phase II study of enzastaurin, a protein kinase C-β (PKCβ) inhibitor, in the treatment of relapsed diffuse large B-cell lymphoma (DLBCL)
Robertson, M
Kahl, B
Vose, J
de Vos, S
Laughlin, M
Flynn, P
Rowland, K
Cruz, J
Goldberg, S
Darnstein, C
Enas, N
Neuberg, D
Savage, K
Thornton, D
Slapak, C
Shipp, M
BLOOD, 2005, 106 (11) : 275A - 275A
[49] Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context
Kuo, Wen-Liang
Liu, Jing
Mauceri, Helena
Vokes, Everett E.
Weichselbaum, Ralph
Rosner, Marsha Rich
Cohen, Ezra Eddy Wyssam
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2814 - 2824
[50] Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-β inhibitor, in healthy subjects
Welch, Pamela A.
Sinha, Vikram P.
Cleverly, Ann L.
Darstein, Christelle
Flanagan, Shawn D.
Musib, Luna C.
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1138 - 1151

← 1 2 3 4 5 →